DK2694056T3 - Terapeutisk behandling - Google Patents

Terapeutisk behandling Download PDF

Info

Publication number
DK2694056T3
DK2694056T3 DK12715421.9T DK12715421T DK2694056T3 DK 2694056 T3 DK2694056 T3 DK 2694056T3 DK 12715421 T DK12715421 T DK 12715421T DK 2694056 T3 DK2694056 T3 DK 2694056T3
Authority
DK
Denmark
Prior art keywords
therapeutic treatment
therapeutic
treatment
Prior art date
Application number
DK12715421.9T
Other languages
English (en)
Inventor
Barry Robert Davies
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK2694056T3 publication Critical patent/DK2694056T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK12715421.9T 2011-04-01 2012-04-02 Terapeutisk behandling DK2694056T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470668P 2011-04-01 2011-04-01
PCT/GB2012/050736 WO2012131399A1 (en) 2011-04-01 2012-04-02 Therapeutic treatment

Publications (1)

Publication Number Publication Date
DK2694056T3 true DK2694056T3 (da) 2020-01-02

Family

ID=45976963

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12715421.9T DK2694056T3 (da) 2011-04-01 2012-04-02 Terapeutisk behandling

Country Status (26)

Country Link
US (2) US9402847B2 (da)
EP (2) EP2694056B1 (da)
JP (1) JP6080837B2 (da)
KR (1) KR101851820B1 (da)
CN (1) CN103442708B (da)
AU (1) AU2012235902B2 (da)
BR (1) BR112013025410A2 (da)
CA (1) CA2831848C (da)
CY (1) CY1122608T1 (da)
DK (1) DK2694056T3 (da)
EA (1) EA027506B1 (da)
ES (1) ES2761311T3 (da)
HR (1) HRP20191927T1 (da)
HU (1) HUE047357T2 (da)
IL (1) IL228589B (da)
LT (1) LT2694056T (da)
ME (1) ME03589B (da)
MX (1) MX357447B (da)
MY (1) MY169449A (da)
PL (1) PL2694056T3 (da)
PT (1) PT2694056T (da)
RS (1) RS59568B1 (da)
SG (1) SG193505A1 (da)
SI (1) SI2694056T1 (da)
WO (1) WO2012131399A1 (da)
ZA (1) ZA201308176B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131399A1 (en) * 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment
KR102222346B1 (ko) * 2013-03-04 2021-03-02 아스트라제네카 아베 조합 치료
CN107670048B (zh) 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (da) 1963-04-04 1900-01-01
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
JP2001519766A (ja) 1996-04-03 2001-10-23 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼの阻害剤
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
HU230338B1 (hu) 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
EA200000098A1 (ru) 1997-08-05 2000-08-28 Пфайзер Продактс Инк. 4-АМИНОПИРРОЛ(3,2-d)ПИРИМИДИНЫ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА НЕЙРОПЕПТИДА Y
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
EE200200711A (et) 2000-06-26 2004-06-15 Pfizer Products Inc. Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
EP1315714B1 (en) 2000-08-31 2005-11-09 F. Hoffmann-La Roche Ag Quinazoline derivatives as alpha-1 adrenergic antagonists
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
WO2002057267A1 (en) 2000-12-01 2002-07-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof
UY27220A1 (es) * 2001-03-23 2002-09-30 Aventis Pharma Sa Combinación de un taxano con una quinasa ciclina-dependiente
US7314936B2 (en) 2002-01-07 2008-01-01 Eisai Co., Ltd. Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
UA81628C2 (uk) * 2002-05-17 2008-01-25 Авентіс Фарма С.А. Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози
WO2004002531A1 (ja) 2002-06-26 2004-01-08 Ono Pharmaceutical Co., Ltd. 血管の収縮または拡張による疾患治療剤
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003265636A1 (en) 2002-09-06 2004-03-29 Smithkline Beecham Corporation Pyrrolo(2, 3-d)pyrimidine-4-yl and purin-6-yl urea compounds
WO2004043380A2 (en) 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
US7524847B2 (en) 2002-12-04 2009-04-28 Eisai R&D Management Co., Ltd. Fused 1,3-dihydro-imidazole ring compounds
EP1444982A1 (de) 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
WO2004080463A1 (en) 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
US20060128956A1 (en) 2003-04-21 2006-06-15 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (Purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
CA2536954C (en) 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
AU2004293026B2 (en) 2003-11-21 2012-01-19 Array Biopharma Inc. AKT protein kinase inhibitors
EP1698375B1 (en) 2003-12-25 2014-04-02 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
WO2007007919A2 (en) 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
CA2880727C (en) 2005-08-31 2019-05-07 Neil P. Desai Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
WO2007027941A2 (en) 2005-08-31 2007-03-08 Abraxis Bioscience, Llc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
JP2009536161A (ja) 2006-04-25 2009-10-08 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2013206A1 (en) 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
EP2029592A1 (en) 2006-04-25 2009-03-04 Astex Therapeutics Limited Pharmaceutical compounds
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
CN101678022A (zh) 2006-12-21 2010-03-24 弗特克斯药品有限公司 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
RS53552B1 (en) * 2007-10-11 2015-02-27 Astrazeneca Ab DERIVATI PIROLO [2,3-D] PIRIMIDINA KAO INHIBITORI PROTEIN KINAZE B
WO2012131399A1 (en) * 2011-04-01 2012-10-04 Astrazeneca Ab Therapeutic treatment

Also Published As

Publication number Publication date
US20160317540A1 (en) 2016-11-03
WO2012131399A1 (en) 2012-10-04
CY1122608T1 (el) 2021-03-12
JP2014509639A (ja) 2014-04-21
HRP20191927T1 (hr) 2020-01-10
EA027506B1 (ru) 2017-08-31
AU2012235902B2 (en) 2015-08-27
ME03589B (me) 2020-07-20
EA201391327A1 (ru) 2014-03-31
ZA201308176B (en) 2015-12-23
JP6080837B2 (ja) 2017-02-15
NZ616410A (en) 2015-09-25
MX2013011413A (es) 2014-05-21
MX357447B (es) 2018-07-10
RS59568B1 (sr) 2019-12-31
US20140121227A1 (en) 2014-05-01
BR112013025410A2 (pt) 2016-12-20
KR20140022856A (ko) 2014-02-25
CN103442708B (zh) 2016-11-09
IL228589B (en) 2019-09-26
EP2694056B1 (en) 2019-10-16
ES2761311T3 (es) 2020-05-19
CA2831848A1 (en) 2012-10-04
CA2831848C (en) 2020-12-22
SI2694056T1 (sl) 2019-12-31
IL228589A0 (en) 2013-12-31
KR101851820B1 (ko) 2018-06-04
CN103442708A (zh) 2013-12-11
HUE047357T2 (hu) 2020-04-28
US9402847B2 (en) 2016-08-02
EP3620159A1 (en) 2020-03-11
PT2694056T (pt) 2019-11-20
MY169449A (en) 2019-04-11
PL2694056T3 (pl) 2020-03-31
LT2694056T (lt) 2019-12-10
AU2012235902A1 (en) 2013-05-02
SG193505A1 (en) 2013-10-30
EP2694056A1 (en) 2014-02-12

Similar Documents

Publication Publication Date Title
CO7020866A2 (es) Péptidos terapéuticos
BR112014007603A2 (pt) métodos de tratamento do câncer
CO6930321A2 (es) Curación de tejidos
BR112013032887A2 (pt) cateter
DK2707030T3 (da) Cancerbehandlinger
FI20116181A (fi) Uusia terapeuttisia vektoreita
EP2906208A4 (en) THERAPEUTIC TREATMENT
DK2760886T3 (da) Immunocytokin-kombinationsterapi
BR112013033974A2 (pt) terapia de combinação
BR112014012880A2 (pt) tratamento imunogênico do câncer
FI20115876A0 (fi) Yhdistelmähoito
DK2489413T3 (da) Behandlingsapparat
DK2783256T3 (da) Terapeutiske briller
CO6880064A2 (es) Métodos terapéuticos
BR112014000742A2 (pt) terapia de combinação de als
CO6801765A2 (es) Isoxazolinas como agentes terapéuticos
FI20115640A0 (fi) Yhdistelmähoito
FI20116093L (fi) Vettä käsittelevä laitos
CO6950447A2 (es) Aparato de tratamiento de espalda
DK2694056T3 (da) Terapeutisk behandling
DK2720533T3 (da) Stimulation device
FI20115020A0 (fi) Käsittely-yksikkö
FI20115905A0 (fi) Käsittelyjärjestely
DK2663304T3 (da) Kombinationsterapi
ES1075603Y (es) Objeto terapeutico